<--- Back to Details
First PageDocument Content
Oncology / Antiemetics / Ketones / Eli Lilly and Company / Aprepitant / Cisplatin / Galantamine / Chemotherapy-induced nausea and vomiting / Angiotensin II receptor antagonist / Chemistry / Medicine / Alcohols
Date: 2014-09-17 13:39:55
Oncology
Antiemetics
Ketones
Eli Lilly and Company
Aprepitant
Cisplatin
Galantamine
Chemotherapy-induced nausea and vomiting
Angiotensin II receptor antagonist
Chemistry
Medicine
Alcohols

Ontario Drug Benefit Formulary/Comparative Drug Index

Add to Reading List

Source URL: www.health.gov.on.ca

Download Document from Source Website

File Size: 198,85 KB

Share Document on Facebook

Similar Documents

Clinical Neutron Therapy System Reference Manual Jonathan Jacky1 Ruedi Risler Radiation Oncology, Box

Clinical Neutron Therapy System Reference Manual Jonathan Jacky1 Ruedi Risler Radiation Oncology, Box

DocID: 1xVse - View Document

Formal Development of a Graphical User Interface for a Radiation Therapy Machine Jonathan Jacky  Jonathan Unger Radiation Oncology Department RC-08 University of Washington

Formal Development of a Graphical User Interface for a Radiation Therapy Machine Jonathan Jacky  Jonathan Unger Radiation Oncology Department RC-08 University of Washington

DocID: 1xViy - View Document

Experience with Z Developing a Control Program for a Radiation Therapy Machine Jonathan Jacky , Jonathan Unger, Michael Patrick and Ruedi Risler Radiation Oncology Box

Experience with Z Developing a Control Program for a Radiation Therapy Machine Jonathan Jacky , Jonathan Unger, Michael Patrick and Ruedi Risler Radiation Oncology Box

DocID: 1xV2d - View Document

Formal Specication and Development of Control System Input/Output Jonathan Jacky Radiation Oncology Department RC-08 University of Washington

Formal Speci cation and Development of Control System Input/Output Jonathan Jacky Radiation Oncology Department RC-08 University of Washington

DocID: 1xUvZ - View Document

European Society for Medical Oncology (ESMOCongress Roche Analyst Audio Webcast Monday, 22 October 2018 Welcome Daniel O’Day, CEO Roche Pharmaceuticals

European Society for Medical Oncology (ESMOCongress Roche Analyst Audio Webcast Monday, 22 October 2018 Welcome Daniel O’Day, CEO Roche Pharmaceuticals

DocID: 1xTgE - View Document